EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseVergleichsstudieOpen Access · CC BY 4.0

Efficacy and Safety of Andexanet Alfa Versus Four Factor Prothrombin Complex Concentrate for Emergent Reversal of Factor Xa Inhibitor Associated Intracranial Hemorrhage: A Systematic Review and Meta-Analysis

Khalid Sarhan iD, Rashad G Mohamed, Reem Reda Elmahdi, Youstina Mohsen, Asmaa Elsayed, Dania Mosaad Zayed, Menna A Elkholi, Nagat Gabr, Enjy M El-Bialy, Ibrahim Serag

Neurocritical Care · 2025-04 · 42 (2) · 701-714

DOI: 10.1007/s12028-024-02130-y ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Neurocritical Care, online erschienen am 08.10.2024. Verfasst von Khalid Sarhan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Mansoura University, Mansoura, Egypt. kwssarhan@std.mans.edu.eg. Hauptthemen laut MEDLINE: Blood Coagulation Factors, Intracranial Hemorrhages, Recombinant Proteins, Factor Xa Inhibitors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mansoura University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Factor Xa inhibitors (FXaI) are increasingly used for anticoagulation therapy, yet their association with intracranial hemorrhage poses a significant challenge. Although andexanet alfa (AA) and four-factor prothrombin complex concentrate (4F-PCC) have shown promise in reversing FXaI effects, their comparative efficacy and safety remain uncertain. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we conducted a literature search on electronic databases to obtain the relevant studies until May 16, 2024. Our primary outcomes were successful anticoagulation reversal, overall mortality (including 30-day and in-hospital mortality), and thromboembolic events. Secondary outcomes were length of hospital and intensive care unit stay and hematoma volume expansion. Data were pooled using a random-effects model. We included 16 eligible studies with a total of 2,977 patients. A statistically significant improvement in hemostatic efficacy rates was in favor of the AA group (risk ratio [RR] 1.10, 95% confidence interval [CI] 1.01–1.20, P = 0.02). Lower overall mortality rates were found in the AA group (RR 0.67, 95% CI 0.51–0.88, P = 0.004). However, no difference was found in 30-day mortality rates (RR 0.82, 95% CI 0.58–1.16, P = 0.26). In terms of thromboembolic events, more events were found in the AA group (RR 1.47, 95% CI 1.01–2.15, P = 0.046). AA was associated with a longer duration of hospital stay compared to 4F-PCC (mean difference [MD] 0.64, 95% CI 0.07–1.22, P = 0.03). Neither a significant difference in length of intensive care unit stay (MD 0.25, 95% CI − 0.36 to 0.86, P = 0.41) nor a significant difference in hematoma volume expansion was reported (MD − 0.89, 95% CI − 3.11 to 1.34, P = 0.435). Our results suggest that AA is superior to 4F-PCC in enhancing the hemostatic efficacy and reducing the overall and in-hospital mortality rates. More thromboembolic events are thought to be associated with the use of AA. However, more studies are required to validate whether the better results of AA in improving hemostatic efficacy are enough to make up for their higher cost and their possible risk of thromboembolic events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood Coagulation FactorsIntracranial HemorrhagesRecombinant ProteinsFactor Xa InhibitorsFactor XaHumansHospital MortalityLength of Stay

Stichwörter der Autor:innen

Andexanet alfaAnticoagulantsIntracerebral hemorrhageProthrombin complex concentratesReversal agents

Substanzen

Blood Coagulation Factorsprothrombin complex concentratesRecombinant ProteinsFactor Xa InhibitorsFactor XaPRT064445

Autor:innen und Institutionen

  • Faculty of Medicine, Mansoura University, Mansoura, Egypt. kwssarhan@std.mans.edu.eg.
  • Mansoura Manchester Program for Medical Education, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
  • Faculty of Medicine, Mansoura University, Mansoura, Egypt.

ORCID-Profile: Khalid Sarhan

Förderung

  • Mansoura University

Zitieren

APA

Sarhan, K., Mohamed, R. G., Elmahdi, R. R., Mohsen, Y., Elsayed, A., Zayed, D. M., Elkholi, M. A., Gabr, N., El-Bialy, E. M., & Serag, I. (2025). Efficacy and Safety of Andexanet Alfa Versus Four Factor Prothrombin Complex Concentrate for Emergent Reversal of Factor Xa Inhibitor Associated Intracranial Hemorrhage: A Systematic Review and Meta-Analysis. Neurocritical Care, 42(2), 701-714. https://doi.org/10.1007/s12028-024-02130-y

Vancouver

Sarhan K, Mohamed RG, Elmahdi RR, Mohsen Y, Elsayed A, Zayed DM, et al. Efficacy and Safety of Andexanet Alfa Versus Four Factor Prothrombin Complex Concentrate for Emergent Reversal of Factor Xa Inhibitor Associated Intracranial Hemorrhage: A Systematic Review and Meta-Analysis. Neurocritical Care. 2025;42(2):701-714. doi:10.1007/s12028-024-02130-y

BibTeX
@article{Sarhan2025,
  author = {Sarhan, Khalid and Mohamed, Rashad G and Elmahdi, Reem Reda and Mohsen, Youstina and Elsayed, Asmaa and Zayed, Dania Mosaad and Elkholi, Menna A and Gabr, Nagat and El-Bialy, Enjy M and Serag, Ibrahim},
  title = {Efficacy and Safety of Andexanet Alfa Versus Four Factor Prothrombin Complex Concentrate for Emergent Reversal of Factor Xa Inhibitor Associated Intracranial Hemorrhage: A Systematic Review and Meta-Analysis},
  journal = {Neurocritical Care},
  year = {2025},
  volume = {42},
  number = {2},
  pages = {701--714},
  doi = {10.1007/s12028-024-02130-y}
}
Kostenlos starten →